MDACC Study No:2009-0186 ( NCT No: NCT01097746)
Title:A Phase II Trial of Bevacizumab with Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma
Principal Investigator:Anil Sood
Treatment Agent:Bevacizumab; Carboplatin; Paclitaxel
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if therapy with
bevacizumab, carboplatin, and weekly doses of paclitaxel is safe and can be
tolerated in patients with newly diagnosed epithelial ovarian, primary
peritoneal, or fallopian tube cancer. Researchers will also study if and how
well this study therapy may help to control the disease.
Hide details for General InformationGeneral Information

Disease Group:Fallopian Tube; Ovary; Peritoneum
Phase of Study:Phase II
Treatment Agents:Bevacizumab
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Genentech
Return Visit:18 weeks (weekly for 6 cycles of 3 weeks each)
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Anil Sood
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-792-6810
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults